IL145475A0 - Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same - Google Patents

Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same

Info

Publication number
IL145475A0
IL145475A0 IL14547500A IL14547500A IL145475A0 IL 145475 A0 IL145475 A0 IL 145475A0 IL 14547500 A IL14547500 A IL 14547500A IL 14547500 A IL14547500 A IL 14547500A IL 145475 A0 IL145475 A0 IL 145475A0
Authority
IL
Israel
Prior art keywords
compounds
same
pharmaceutical compositions
compositions containing
impdh enzyme
Prior art date
Application number
IL14547500A
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL145475A0 publication Critical patent/IL145475A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
IL14547500A 1999-03-19 2000-03-17 Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same IL145475A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12550799P 1999-03-19 1999-03-19
US17488200P 2000-01-07 2000-01-07
PCT/US2000/007129 WO2000056331A1 (en) 1999-03-19 2000-03-17 Inhibitors of impdh enzyme

Publications (1)

Publication Number Publication Date
IL145475A0 true IL145475A0 (en) 2002-06-30

Family

ID=26823644

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14547500A IL145475A0 (en) 1999-03-19 2000-03-17 Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same
IL145475A IL145475A (en) 1999-03-19 2001-09-16 IMPDH enzyme inhibitor compounds and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145475A IL145475A (en) 1999-03-19 2001-09-16 IMPDH enzyme inhibitor compounds and pharmaceutical preparations containing them

Country Status (24)

Country Link
US (4) US6498178B2 (cs)
EP (2) EP1178797B1 (cs)
JP (3) JP4184610B2 (cs)
KR (1) KR100652535B1 (cs)
CN (1) CN1196687C (cs)
AP (1) AP1498A (cs)
AR (1) AR029341A1 (cs)
AU (1) AU769383B2 (cs)
BG (1) BG65563B1 (cs)
BR (1) BR0009167A (cs)
CA (1) CA2367017C (cs)
CZ (1) CZ301802B6 (cs)
EA (1) EA004141B1 (cs)
EE (1) EE200100492A (cs)
ES (1) ES2405316T3 (cs)
HU (1) HUP0201214A3 (cs)
IL (2) IL145475A0 (cs)
NO (1) NO321932B1 (cs)
NZ (1) NZ514540A (cs)
OA (1) OA11848A (cs)
PL (1) PL211562B1 (cs)
SK (1) SK13332001A3 (cs)
TR (1) TR200103428T2 (cs)
WO (1) WO2000056331A1 (cs)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133649C (zh) 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
AU769383B2 (en) * 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
SI2305255T1 (sl) * 2001-12-03 2012-10-30 Bayer Healthcare Llc Arilsečninske spojine v kombinaciji z drugimi citostatičnimi ali citotoksičnimi sredstvi za zdravljenje človeških rakov
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
EP1575579B1 (en) * 2002-12-06 2009-03-04 Vertex Pharmaceuticals Incorporated Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20050090450A1 (en) 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MXPA05012486A (es) 2003-05-20 2006-07-03 Bayer Pharmaceuticals Corp Diaril ureas para enfermedades mediadas por pdgfr.
EP2341065A3 (en) 2003-07-18 2012-06-20 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4a protease
WO2005009961A2 (en) 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DE10336185A1 (de) * 2003-08-07 2005-02-24 Bayer Chemicals Ag Enantiomerenangereicherte 1-Phenylethylamine
US7156615B2 (en) * 2003-08-21 2007-01-02 Siemens Vdo Automotive Inc. Fan shroud structure for reducing resonance, improving stiffness and manufacturability
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
JP2007505603A (ja) * 2003-09-12 2007-03-15 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド プロテアーゼ活性および肝障害のための動物モデル
AR045769A1 (es) 2003-09-18 2005-11-09 Vertex Pharma Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c)
KR20120010278A (ko) 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
CA2551074A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
CN1938332B (zh) 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
EP1727791A1 (en) * 2004-03-23 2006-12-06 Vertex Pharmaceuticals Incorporated Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US20070219224A1 (en) * 2004-05-21 2007-09-20 Uab Research Foundation, The Compositions and Methods Relating to Pyrimidine Synthesis Inhibitors
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
RU2007116265A (ru) * 2004-10-01 2008-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибирование протеазы ns3-ns4a вируса hcv
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
CN101175718A (zh) * 2005-05-09 2008-05-07 沃泰克斯药物股份有限公司 制备联芳基脲及其类似物的方法
AU2006249921A1 (en) * 2005-05-26 2006-11-30 Vertex Pharmaceuticals Incorporated Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
DK1912997T3 (da) 2005-07-29 2012-01-02 Tibotec Pharm Ltd Makrocycliske inhibitorer af hepatitis C virus
TWI375670B (en) 2005-07-29 2012-11-01 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PL1913015T3 (pl) 2005-07-29 2014-04-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
WO2007014921A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
EP1912996B1 (en) 2005-07-29 2012-06-20 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
ES2359939T3 (es) 2005-07-29 2011-05-30 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
NZ565540A (en) 2005-08-02 2011-06-30 Vertex Pharma Inhibitors of serine proteases
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP2392588A3 (en) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8791110B2 (en) 2006-02-01 2014-07-29 Siga Technologies, Inc. Anti-arenaviral compounds
WO2007120374A2 (en) * 2006-02-01 2007-10-25 Siga Technologies, Inc. Anti-arenaviral compounds
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
FR2901273B1 (fr) * 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
WO2008040778A2 (en) 2006-10-04 2008-04-10 Tibotec Pharmaceuticals Ltd. Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
ES2470568T3 (es) 2006-11-17 2014-06-24 Janssen R&D Ireland Inhibidores macroc�clicos del virus de la hepatitis C
EP2118091B1 (en) 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Pyrimidine substituted macrocyclic hcv inhibitors
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
JP5443360B2 (ja) * 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
WO2009148961A2 (en) * 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
PL2331554T3 (pl) 2008-08-14 2013-08-30 Janssen R&D Ireland Makrocykliczne pochodne indolu użyteczne jako inhibitory wirusa zapalenia wątroby typu C
AU2009322393B2 (en) 2008-12-03 2017-02-02 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
JP2012510525A (ja) 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
EA201190224A1 (ru) 2009-03-27 2012-03-30 Пресидио Фармасьютикалс, Инк. Ингибиторы гепатита c, содержащие конденсированные кольца
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
SG182589A1 (en) 2010-01-29 2012-08-30 Vertex Pharma Therapies for treating hepatitis c virus infection
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
CN103097356B (zh) 2010-06-24 2016-01-13 爱尔兰詹森科学公司 13-环己基-3-甲氧基-6-[甲基-(2-{2-[甲基-(氨磺酰基)-氨基]-乙氧基}-乙基)-氨基甲酰基]-7H-吲哚并-[2,1-a]-[2]-苯并氮杂*-10-羧酸的制备
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
JP5731004B2 (ja) 2010-10-26 2015-06-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
CN102985104A (zh) 2011-02-25 2013-03-20 麦德托尼克公司 在干扰素-α治疗方案中使用药代动力学分布和药效动力学分布的方法和系统
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
BR112013032188A2 (pt) 2011-06-23 2016-12-20 Digna Biotech Sl composição, produto e método para tratar pacientes com hepatite c crônica
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
CN103917541B (zh) 2011-10-10 2016-08-17 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
RU2014127848A (ru) 2011-12-16 2016-02-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы hcv ns5a
EA024297B1 (ru) 2011-12-20 2016-09-30 Рибосайенс Ллк 2',4'-дифтор-2'-метилзамещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
HUE033332T2 (en) 2011-12-20 2017-11-28 Riboscience Llc 4'-Azido-3'-fluoro-substituted nucleoside derivatives as inhibitors of HCV RNA replication
BR112014016157A8 (pt) 2011-12-28 2017-07-04 Janssen R&D Ireland derivados heterobicíclicos como inibidores de vhc
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
CN104185624B (zh) 2012-02-24 2016-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
BR112015017414A2 (pt) 2013-01-23 2017-07-11 Hoffmann La Roche derivados de triazol antivirais
CA2900319A1 (en) 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Antiviral compounds
HK1217294A1 (zh) 2013-05-16 2017-01-06 Riboscience Llc 4'-氟-2'-甲基取代的核苷衍生物
PE20160119A1 (es) 2013-05-16 2016-02-24 Riboscience Llc Derivados de nucleosido 4'-azido, 3'-desoxi-3'-fluoro sustituido
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
CA3075645A1 (en) 2017-09-21 2019-03-28 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
DK180212B1 (en) * 2018-05-07 2020-08-19 Apple Inc USER INTERFACE FOR CREATING AVATAR
CN109970675A (zh) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 一组硫脲化合物及其制备方法和应用
JOP20200326A1 (ar) 2018-06-19 2020-12-14 Novartis Ag مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
DE4228000A1 (de) * 1992-08-24 1994-03-03 Bayer Ag 3-Aryl-triazin-2,4-dione
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5380879A (en) 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
AU723730B2 (en) * 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
US6128582A (en) * 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
US5932600A (en) * 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU769383B2 (en) * 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
ES2200902T3 (es) * 1999-06-25 2004-03-16 Vertex Pharmaceuticals Incorporated Profarmacos de carbamato inhibidores de la impdh.
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US6939375B2 (en) * 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
US6471980B2 (en) * 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections

Also Published As

Publication number Publication date
NO321932B1 (no) 2006-07-24
OA11848A (en) 2006-03-08
JP2008115186A (ja) 2008-05-22
WO2000056331A1 (en) 2000-09-28
CZ20013349A3 (cs) 2002-03-13
HUP0201214A3 (en) 2002-11-28
CZ301802B6 (cs) 2010-06-30
CN1347318A (zh) 2002-05-01
US6498178B2 (en) 2002-12-24
JP4184610B2 (ja) 2008-11-19
NZ514540A (en) 2003-11-28
PL211562B1 (pl) 2012-05-31
US7087642B2 (en) 2006-08-08
EP1178797A1 (en) 2002-02-13
EP1964561A1 (en) 2008-09-03
CA2367017C (en) 2009-05-26
JP2002539258A (ja) 2002-11-19
EE200100492A (et) 2002-12-16
BG106020A (en) 2002-06-28
EP1178797A4 (en) 2003-05-02
IL145475A (en) 2006-12-10
TR200103428T2 (tr) 2002-04-22
US20020111378A1 (en) 2002-08-15
JP2008255116A (ja) 2008-10-23
NO20014535L (no) 2001-11-19
JP4227182B2 (ja) 2009-02-18
ES2405316T3 (es) 2013-05-30
AP1498A (en) 2005-11-21
AU3757700A (en) 2000-10-09
AP2001002298A0 (en) 2001-12-31
SK13332001A3 (sk) 2002-02-05
PL350911A1 (en) 2003-02-10
US8268873B2 (en) 2012-09-18
US7432290B2 (en) 2008-10-07
EA200100992A1 (ru) 2002-02-28
CA2367017A1 (en) 2000-09-28
EA004141B1 (ru) 2004-02-26
BG65563B1 (bg) 2008-12-30
AU769383B2 (en) 2004-01-22
KR20010112354A (ko) 2001-12-20
US20090030051A1 (en) 2009-01-29
US20040029939A1 (en) 2004-02-12
BR0009167A (pt) 2001-12-26
CN1196687C (zh) 2005-04-13
US20050148644A1 (en) 2005-07-07
EP1178797B1 (en) 2013-02-20
HUP0201214A2 (en) 2002-08-28
NO20014535D0 (no) 2001-09-18
AR029341A1 (es) 2003-06-25
KR100652535B1 (ko) 2006-12-01

Similar Documents

Publication Publication Date Title
IL145475A0 (en) Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same
IL148517A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL150077A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL149883A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL139479A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL144910A0 (en) Cyclic compounds and pharmaceutical compositions containing the same
IL150224A0 (en) Lipopeptides and pharmaceutical compositions containing the same
IL144977A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
IL150223A0 (en) Lipopeptides and pharmaceutical compositions containing the same
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP0105113A3 (en) Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
HUP0103256A3 (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds
IL138899A0 (en) Amidene derivatives and pharmaceutical compositions containing the same
IL149757A0 (en) Aminothiazole derivatives and pharmaceutical compositions containing the same
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
IL135176A0 (en) Benzothiazole derivatives and pharmaceutical compositions containing the same
IL147778A0 (en) Pharmaceutical compositions containing cyclobenzaprine
IL144592A0 (en) Heterocyclic aromatic compounds and pharmaceutical compositions containing the same
IL141456A0 (en) Rhodanine derivatives and pharmaceutical compositions containing the same
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
IL148489A0 (en) Quinazoline compounds and pharmaceutical compositions containing them
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees